<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770689</url>
  </required_header>
  <id_info>
    <org_study_id>MS100036_0020</org_study_id>
    <secondary_id>2018-002275-18</secondary_id>
    <nct_id>NCT03770689</nct_id>
  </id_info>
  <brief_title>Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer</brief_title>
  <official_title>A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Capecitabine and Radiotherapy in Participants With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to define maximum tolerated dose (MTD), recommended Phase II
      dose (RP2D) of M3814 in combination with capecitabine and radiotherapy (RT) in Phase Ib and
      to evaluate the efficacy of M3814 in terms of Pathological Clinical Response (pCR)/Clinical
      Complete Response (cCR) when administered in combination with capecitabine and RT versus
      placebo, capecitabine, and RT in Phase II.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">August 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Number of Participants Experiencing a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Time from first dose of study drug to end of chemo radiotherapy with a final assessment at 4 weeks post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Proportion of Participants With Pathological Complete Response (pCR) and Clinical Complete Response (cCR)</measure>
    <time_frame>Post-surgery at Day 119 (pCR); 2 weeks prior-surgery (cCR)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Occurrence of Treatment-related Adverse Events (TEAEs) According to National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5.0</measure>
    <time_frame>Time from first dose of study drug to final assessment at 5 years for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Number of Participants With Abnormalities (Grade Greater than or equals to (â‰¥) 3) in Laboratory Test Values</measure>
    <time_frame>Time from first study drug to final assessment at 5 years for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Number of Participants With Markedly Abnormal Vital Sign Measurements</measure>
    <time_frame>Time from first dose of study drug to final assessment at 5 years for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Time from first dose of study drug to final assessment at 5 years for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Overall Survival</measure>
    <time_frame>Time from first dose of study drug to final assessment at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Disease-free Survival</measure>
    <time_frame>Time from first study drug to final assessment at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Best Overall Response Assessed by Investigator</measure>
    <time_frame>Time from first dose of study drug until surgery at Day 119</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Time from Surgery to Local Recurrence and Distant Metastasis</measure>
    <time_frame>Time from surgery to final assessment at 5 years for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Maximum Observed Drug Concentration (Cmax) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day (FD1) and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Area Under the Plasma Concentration-time Curve From Time Zero to Last Sampling Time (tlast) (AUC0-t) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Time to Reach Maximum Plasma Concentration (tmax) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Total Body Clearance of Drug From Plasma Following Oral Administration (CL/f) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9 for each phase for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Apparent Volume of Distribution (Vz/f) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9 for each phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Apparent Terminal Half-life (t1/2) of M3814</measure>
    <time_frame>Pre-dose, 1, 2, 3 and 4 hour post-dose on Fraction Day 1 and Fraction Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival</measure>
    <time_frame>Time from randomization to final assessment at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Best Overall Response Assessed by Investigator</measure>
    <time_frame>Time from randomization until Day 119</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Neoadjuvant Rectal Score</measure>
    <time_frame>Post-surgery at Day 119</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Proportion of Participants With/Without Surgical Intervention</measure>
    <time_frame>Time from randomization to final assessment at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of Participants With R0 Resection (No Residual Tumor)</measure>
    <time_frame>Post-surgery at Day 119</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Quality of Life (QoL) Measured Using European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>Time from randomization to assessment at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Quality of Life (QoL) Measured Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Colorectal Cancer (EORTC-CR29)</measure>
    <time_frame>Time from randomization to assessment at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Quality of Life (QoL) Measured Using EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Time from randomization to assessment at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib and II: Proportion of Participants With Pathological Complete Response (pCR)</measure>
    <time_frame>Post-surgery at Day 119</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Proportion of Participants With Clinical Complete Response (cCR)</measure>
    <time_frame>Time from first study drug until 1 to 2 weeks prior to surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Proportion of Participants With Clinical Complete Response (cCR)</measure>
    <time_frame>Time from randomization until surgery at Day 119</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase Ib: M3814 + Capecitabine + RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M3814 + capecitabine + RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Placebo + capecitabine + RT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase Ib: M3814</intervention_name>
    <description>Participants will receive M3814 at an escalated dose starting from 50 mg once daily 5 days per week in first cohort up to week 6 and for the next cohorts M3814 dose will be determined by the Safety Monitoring Committee (SMC) guided by a Bayesian 2-parameter logistic regression model with overdose control.</description>
    <arm_group_label>Phase Ib: M3814 + Capecitabine + RT</arm_group_label>
    <other_name>Peposertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Participants will receive capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week in Phase Ib and Phase II up to week 6.</description>
    <arm_group_label>Phase II: M3814 + capecitabine + RT</arm_group_label>
    <arm_group_label>Phase II: Placebo + capecitabine + RT</arm_group_label>
    <arm_group_label>Phase Ib: M3814 + Capecitabine + RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy (RT)</intervention_name>
    <description>Participants will receive RT of approximately 50 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions (corresponding to 5 to 5.5 weeks) Phase Ib and Phase II.</description>
    <arm_group_label>Phase II: M3814 + capecitabine + RT</arm_group_label>
    <arm_group_label>Phase II: Placebo + capecitabine + RT</arm_group_label>
    <arm_group_label>Phase Ib: M3814 + Capecitabine + RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase II: M3814</intervention_name>
    <description>Participants will receive M3814 50 mg or matching placebo at the RP2D once daily 5 days per week up to week 6.</description>
    <arm_group_label>Phase II: M3814 + capecitabine + RT</arm_group_label>
    <other_name>Peposertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase II: Placebo</intervention_name>
    <description>Participants will receive Placebo matched to M3814 for 5 days per week up to week 6.</description>
    <arm_group_label>Phase II: Placebo + capecitabine + RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have an Eastern Cooperative Oncology Group Performance Status less
             than or equals to (â‰¤) 1

          -  Participants who have histologically confirmed and localized resectable rectal cancer
             (Stage III).

          -  Participants who received induction chemotherapy are allowed to be enrolled to this
             study except this induction is resulting in complete response.

          -  Participants who have lower edge of the tumor located in rectum

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Male participants if they agree to the following during the study intervention period
             and for at least 12 weeks after the last dose of study intervention

          -  Female participants are eligible if not pregnant or breastfeeding

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with history of any other significant medical disease or psychiatric
             conditions that might in the assessment of the Investigator preclude safe
             participation in the study

          -  Participants with history of difficulty swallowing, malabsorption, or other chronic
             gastrointestinal disease or conditions that may hamper compliance and/or absorption of
             the study intervention

          -  Unstable cardiovascular function within 6 months prior to enrollment

          -  Hypertension uncontrolled by medication (ie, systolic blood pressure &gt;= 150 millimeter
             of mercury (mmHg) and diastolic blood pressure &gt;= 90 mmHg)

          -  Participants with history of other malignant disease within the past 5 years, other
             than successfully treated basal carcinoma of the skin or carcinoma in situ of the
             cervix

          -  Participants with known human immunodeficiency virus positivity, known active
             hepatitis (for example, hepatitis B virus or hepatitis C virus), current alcohol
             abuse, or cirrhosis

          -  Participants with ongoing active infection other than human immunodeficiency virus,
             hepatitis B virus, or hepatitis C virus, or treatment with a live attenuated vaccine
             within 4 weeks of dosing

          -  Participants with concomitant use of H2-blocker or proton pump inhibitors (PPIs) (or
             unable to stop at least 5 days prior to the first treatment). Note that calcium
             carbonate is acceptable

          -  Participation in any interventional clinical study within 28 days prior to Screening
             or during participation in this study

          -  Other protocol defined exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karyn Goodman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University - Pediatric Respiratory Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>michael.cecchini@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Cecchini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Goel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>10042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tony Philip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center (MSKCC) - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Romesser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center - Hematology/Oncology</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Nemunaitis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med. Univ. of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carolyn Britten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ki Y Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma Holliday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaume Capdevila Castillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rocio G Garcia Carbonero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia Gil Calle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susana Rosello Keranen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS100036_0020</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DNA-PK inhibitor</keyword>
  <keyword>M3814</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>EMD Serono, Inc. is committed to sharing patient-level data and supporting documentation from applicable studies according to company policies. Further information on data sharing and how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

